- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06149286
Eine Studie, um herauszufinden, ob Odronextamab in Kombination mit Lenalidomid sicher ist und bei Teilnehmern mit follikulärem Lymphom und Marginalzonenlymphom besser wirkt als Rituximab in Kombination mit Lenalidomid (OLYMPIA-5)
Eine offene, randomisierte Phase-3-Studie zum Vergleich der Wirksamkeit und Sicherheit von Odronextamab (REGN1979), einem bispezifischen Anti-CD20 x Anti-CD3-Antikörper, in Kombination mit Lenalidomid im Vergleich zu Rituximab in Kombination mit Lenalidomid-Therapie bei rezidivierten/refraktären Teilnehmern mit Follikel Lymphom und Randzonenlymphom (OLYMPIA-5)
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's Lymphoma (NHL).
This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled).
The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before.
The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug in combination with lenalidomide
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-Mail: clinicaltrials@regeneron.com
Studienorte
-
-
New South Wales
-
Liverpool, New South Wales, Australien, 2170
- Rekrutierung
- Liverpool Hospital
-
Waratah, New South Wales, Australien, 2298
- Rekrutierung
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa, Queensland, Australien, 4217
- Rekrutierung
- Pindara Private Hospital
-
-
Tasmania
-
Hobart, Tasmania, Australien, 7000
- Rekrutierung
- Royal Hobart Hospital
-
-
Victoria
-
East Melbourne, Victoria, Australien, 3121
- Rekrutierung
- Epworth Freemasons
-
-
-
-
-
Antwerp, Belgien, 2060
- Rekrutierung
- Ziekenhuis Netwerk Antwerpen Stuivenberg
-
Brussels, Belgien, 1000
- Rekrutierung
- Institut Jules Bordet
-
-
Namur
-
Yvoir, Namur, Belgien, 5530
- Rekrutierung
- Centre Hospitalier Universitaire at Universite Catholique de Louvain Namur
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgien, 9000
- Rekrutierung
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, Belgien, 8800
- Rekrutierung
- Algemeen Ziekenhuis AZ Delta
-
-
-
-
-
Rio de Janeiro, Brasilien, 20231050
- Rekrutierung
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo, Brasilien, 01321000
- Rekrutierung
- A Beneficencia Portuguesa de Sao Paulo, Oncology House
-
São Paulo, Brasilien, 01308-050
- Rekrutierung
- Hospital Sirio Libanes
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40285-000
- Rekrutierung
- Hospital Sao Rafael
-
-
Federal District
-
Brasília, Federal District, Brasilien, 70200-730
- Rekrutierung
- Hospital Sirio Libanes Brasilia
-
-
Paraná
-
Cascavel, Paraná, Brasilien, 85806-300
- Rekrutierung
- Uopeccan Hospital do Cancer de Cascavel
-
Curitiba, Paraná, Brasilien, 81520-060
- Rekrutierung
- Hospital Erasto Gaertner
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- Rekrutierung
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90110-270
- Rekrutierung
- Centro Gaucho Integrado
-
-
São Paulo
-
Jaú, São Paulo, Brasilien, 17210-080
- Rekrutierung
- Amaral Carvalho Hospital
-
-
-
-
-
Halle, Deutschland, 6120
- Rekrutierung
- University Hospital Halle Saale
-
Kiel, Deutschland, 24116
- Rekrutierung
- Stadtisches Krankenhaus Kiel
-
Neuss, Deutschland, 41462
- Rekrutierung
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
Baden-Wurttemberg
-
Mutlangen, Baden-Wurttemberg, Deutschland, 73557
- Rekrutierung
- Stauferklinikum
-
Stuttgart, Baden-Wurttemberg, Deutschland, 70376
- Rekrutierung
- Robert-Bosch-Krankenhaus
-
-
Bavaria
-
Munich, Bavaria, Deutschland, 80337
- Rekrutierung
- LMU Klinikum
-
Munich, Bavaria, Deutschland, 81675
- Rekrutierung
- TUM Fakultat fur Medizin - Klinikum Rechts der Isar
-
-
Hesse
-
Frankfurt am Main, Hesse, Deutschland, 15236
- Rekrutierung
- Clinic Frankfurt (Oder)
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Deutschland, 45122
- Rekrutierung
- University Hospital Essen
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Deutschland, 55131
- Rekrutierung
- Universitatsmedizin der Johannes-Gutenberg Universitat Mainz
-
-
-
-
-
Avignon, Frankreich, 84000
- Rekrutierung
- Centre Hospitalier d'Avignon
-
Montpellier, Frankreich, 34290
- Rekrutierung
- Centre Hospitalier Universitaire (CHU) Montpellier
-
Paris, Frankreich, 75010
- Rekrutierung
- Hopital Saint Louis
-
Paris, Frankreich, 75571
- Rekrutierung
- Assistance Publique-Hopitaux de Paris (AP-HP)
-
Saint-Cloud, Frankreich, 92210
- Rekrutierung
- Institut Curie
-
-
Bouches Du Rhone
-
Marseille, Bouches Du Rhone, Frankreich, 13009
- Rekrutierung
- Institut Paoli-Calmettes
-
-
Brittany Region
-
Rennes, Brittany Region, Frankreich, 35033
- Rekrutierung
- CHU de Rennes
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Frankreich, 37044
- Rekrutierung
- Centre Hospitalier Regional Universitaire de Tours
-
-
Gironde
-
Bordeaux, Gironde, Frankreich, 33077
- Rekrutierung
- Polyclinique Bordeaux Nord Aquitaine
-
Pessac, Gironde, Frankreich, 33600
- Rekrutierung
- Centre Francois Magendie
-
-
Nord
-
Lille, Nord, Frankreich, 5900
- Rekrutierung
- Hopital Saint Vincent-de-Paul
-
-
Normandy
-
Rouen, Normandy, Frankreich, 76038
- Rekrutierung
- Centre Henri Becquerel
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Frankreich, 44093
- Rekrutierung
- Nantes University Hospital
-
-
Savoie
-
Chambéry, Savoie, Frankreich, 73000
- Rekrutierung
- Centre Hospitalier Metropole Savoie
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Frankreich, 95100
- Rekrutierung
- Hopital Victor Dupouy Argenteuil
-
Bobigny, Île-de-France Region, Frankreich, 93000
- Rekrutierung
- Avicenne Hospital
-
Villejuif, Île-de-France Region, Frankreich, 94800
- Rekrutierung
- Gustave Roussy
-
-
-
-
-
Ashdod, Israel, 7747629
- Rekrutierung
- Assuta Ashdod Medical Center
-
Jerusalem, Israel, 91200
- Rekrutierung
- Hadassah Medical Center
-
Nahariya, Israel, 2210001
- Rekrutierung
- Galilee Medical Center
-
Petah Tikva, Israel, 49100
- Rekrutierung
- Rabin Medical Center
-
Ramat Gan, Israel, 5265601
- Rekrutierung
- Chaim Sheba Medical Center
-
Tel Aviv, Israel, 64239
- Rekrutierung
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv, Israel, 6971028
- Rekrutierung
- Assuta Medical Centers
-
-
-
-
-
Bologna, Italien, 40138
- Rekrutierung
- University of Bologna Dipartimento di Medicina Specialistica Diagnostica e Sperimentale
-
Brescia, Italien, 25123
- Rekrutierung
- Azienda Ospedaliera Spedali Civili di Brescia
-
Milan, Italien, 20141
- Rekrutierung
- Istituto Europeo di Oncologia
-
Milan, Italien, 20162
- Rekrutierung
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan, Italien, 20122
- Rekrutierung
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena, Italien, 41124
- Rekrutierung
- A.O.U. di Modena
-
Naples, Italien, 80131
- Rekrutierung
- Federico II University
-
Novara, Italien, 28100
- Rekrutierung
- AOU Maggiore della Carita
-
Pavia, Italien, 27100
- Rekrutierung
- Fondazione IRCCS Policlinico San Matteo
-
Perugia, Italien, 06132
- Rekrutierung
- Azienda Ospedaliera di Perugia
-
Ravenna, Italien, 48121
- Rekrutierung
- Ospedale Santa Maria delle Croci
-
Udine, Italien, 33100
- Rekrutierung
- Santa Maria della Misericordia
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italien, 47014
- Rekrutierung
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Genova
-
Genoa, Genova, Italien, 16132
- Rekrutierung
- Ospedale Policlinico San Martino IRCCS
-
-
Monza E Brianza
-
Monza, Monza E Brianza, Italien, 20900
- Rekrutierung
- S Gerardo Hospital
-
-
Piedmont
-
Turin, Piedmont, Italien, 10126
- Rekrutierung
- A.O.U. Citta della Salute e della Scienza di Torino
-
-
Pordenone
-
Aviano, Pordenone, Italien, 33081
- Rekrutierung
- Centro Di Riferimento Oncologico (CRO), Aviano, National Cancer Institute
-
-
Torino
-
Candiolo, Torino, Italien, 10060
- Rekrutierung
- Candiolo Cancer Institute, FPO, IRCCS
-
-
-
-
Johor
-
Johor Bahru, Johor, Malaysia, 80100
- Rekrutierung
- Hospital Sultanah Aminah Jhor Bahru
-
-
Negeri / Wilayah Persekutuan
-
Kuala Lumpur, Negeri / Wilayah Persekutuan, Malaysia, 50603
- Rekrutierung
- University of Malaya Medical Centre
-
-
Sabah
-
Kota Kinabalu, Sabah, Malaysia, 88586
- Rekrutierung
- Hospital Queen Elizabeth
-
-
Selangor
-
Ampang, Selangor, Malaysia, 68000
- Rekrutierung
- Hospital Ampang
-
Subang Jaya, Selangor, Malaysia, 47500
- Rekrutierung
- Subang Jaya Medical Center
-
-
-
-
-
Bydgoszcz, Polen, 85-168
- Zurückgezogen
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Katowice, Polen, 40-519
- Rekrutierung
- Pratia Onkologia Katowice
-
Lodz, Polen, 93-513
- Rekrutierung
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Warsaw, Polen, 02-781
- Rekrutierung
- Narodowy Instytut Onkologii
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-048
- Rekrutierung
- In-Vivo Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Wałbrzych, Lower Silesian Voivodeship, Polen, 58-309
- Rekrutierung
- Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu
-
Wroclaw, Lower Silesian Voivodeship, Polen, 50-367
- Rekrutierung
- Uniwersytecki Szpital Kliniczny
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-090
- Rekrutierung
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Centrum Innowacyjnych Terapii
-
-
Malopolska
-
Krakow, Malopolska, Polen, 30-510
- Rekrutierung
- Pratia MCM Krakow
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen, 80-952
- Rekrutierung
- Uniwersyteckie Centrum Kliniczne
-
-
Wielkopolska
-
Poznan, Wielkopolska, Polen, 60185
- Abgeschlossen
- Pratia Poznan Medical Center
-
Skorzewo, Wielkopolska, Polen, 60185
- Rekrutierung
- Aidport Sp. z o.o.
-
-
-
-
-
Barcelona, Spanien, 08036
- Rekrutierung
- Hospital Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Rekrutierung
- University Hospital Vall d'Hebron
-
Barcelona, Spanien, 08041
- Rekrutierung
- Hospital de la Santa Creu i Sant Pau
-
Granada, Spanien, 18014
- Rekrutierung
- Hospital Virgen De Las Nieves De Granada
-
Madrid, Spanien, 28034
- Rekrutierung
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanien, 28050
- Rekrutierung
- Hospital Universitario HM Sanchinarro
-
Madrid, Spanien, 28040
- Rekrutierung
- Fundacion Jimenez Diaz University Hospital
-
Madrid, Spanien, 28041
- Rekrutierung
- Hospital Universitario12 de Octubre
-
Salamanca, Spanien, 37007
- Rekrutierung
- Hospital Universitario de Salamanca
-
Seville, Spanien, 41013
- Rekrutierung
- University Hospital Virgen del Rocio
-
Valencia, Spanien, 46017
- Rekrutierung
- University Hospital Doctor Peset
-
Valencia, Spanien, 46009
- Rekrutierung
- Instituto Valenciano de Oncologia
-
-
A Coruna
-
Santiago de Compostela, A Coruna, Spanien, 15706
- Rekrutierung
- University Hospital of Santiago de Compostela
-
-
Balearic Islands
-
Palma, Balearic Islands, Spanien, 07120
- Rekrutierung
- Son Espases University Hospital
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 08908
- Rekrutierung
- Institut Catala d'Oncologia
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Rekrutierung
- Hospital Universitario Marques de Valdecilla
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spanien, 28223
- Rekrutierung
- Hospital Universitario Quironsalud Madrid
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spanien, 33011
- Rekrutierung
- Hospital Universitario Central de Asturias
-
-
-
-
-
Busan, Südkorea, 49241
- Rekrutierung
- Pusan National University Hospital
-
Busan, Südkorea, 47392
- Rekrutierung
- Inje University Busan Paik Hospital
-
Daegu, Südkorea, 42415
- Zurückgezogen
- Yeyungnam University Medical Center
-
Seoul, Südkorea, 05505
- Rekrutierung
- Asan Medical Center
-
Seoul, Südkorea, 06351
- Rekrutierung
- Samsung Medical Center
-
Seoul, Südkorea, 3080
- Rekrutierung
- Seoul National University Hospital
-
Seoul, Südkorea, 07345
- Rekrutierung
- Yeouido St. Marys Hospital
-
Seoul, Südkorea, 03722
- Rekrutierung
- Yonsei University Health System
-
Seoul, Südkorea, 137-701
- Rekrutierung
- Seoul St Marys Hospital
-
Ulsan, Südkorea, 44033
- Rekrutierung
- Ulsan University Hospital
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, Südkorea, 16247
- Rekrutierung
- St. Vincents Hospital - The Catholic University of Korea
-
-
Jeollabuk
-
Jeonju, Jeollabuk, Südkorea, 54907
- Rekrutierung
- Jeonbuk National University Hospital
-
-
Namdong-Gu
-
Incheon, Namdong-Gu, Südkorea, 21565
- Rekrutierung
- Gachon University Gil Medical Center
-
-
-
-
-
Changhua, Taiwan, 500-06
- Rekrutierung
- Changhua Christian Hospital
-
Changhua, Taiwan, 50008
- Rekrutierung
- Show Chwan Memorial Hospital
-
Kaohsiung City, Taiwan, 83301
- Rekrutierung
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City, Taiwan, 80756
- Rekrutierung
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwan, 23561
- Rekrutierung
- Taipei Medical University - Shuang Ho Hospital
-
Tainan, Taiwan, 701
- Rekrutierung
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- Rekrutierung
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Rekrutierung
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 11490
- Rekrutierung
- Tri-Service General Hospital
-
Taipei, Taiwan, 116
- Rekrutierung
- Taipei Municipal Wan Fang Hospital
-
Taoyuan City, Taiwan, 333
- Rekrutierung
- Chang Gung Memorial Hospital
-
-
Chiayi County
-
Buzi, Chiayi County, Taiwan, 613
- Rekrutierung
- Chang Gung Medical Foundation Chia Yi Branch
-
-
-
-
-
Bangkok, Thailand, 10700
- Rekrutierung
- Sriraj Hospital
-
Chiang Mai, Thailand, 50200
- Rekrutierung
- Chiang Mai University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok, Krung Thep Maha Nakhon [Bangko], Thailand, 10330
- Rekrutierung
- Chulalongkorn University
-
-
-
-
-
Brno, Tschechien, 62500
- Rekrutierung
- Fakultni Nemocnice Brno
-
Prague, Tschechien, 10034
- Rekrutierung
- University Hospital Kralovske Vinohrady
-
Prague, Tschechien, 12808
- Rekrutierung
- Vseobecna Fakultni Nemocnice V Praze
-
-
East Bohemia
-
Hradec Králové, East Bohemia, Tschechien, 50005
- Rekrutierung
- University Hospital Hradec Kralove
-
-
-
-
-
Istanbul, Türkei (türkiye), 34093
- Rekrutierung
- Istanbul University, Istanbul Medical Faculty
-
Izmir, Türkei (türkiye), 35340
- Rekrutierung
- Dokuz Eylul University
-
Izmir, Türkei (türkiye), 35100
- Rekrutierung
- Ege University
-
Sakarya, Türkei (türkiye), 54290
- Rekrutierung
- Sakarya University Medical Faculty
-
Samsun, Türkei (türkiye), 55270
- Rekrutierung
- Ondokuz Mayıs University
-
Zonguldak, Türkei (türkiye), 67600
- Rekrutierung
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak, Ankara, Türkei (türkiye), 06620
- Rekrutierung
- Ankara University Faculty of Medicine
-
Yenimahalle, Ankara, Türkei (türkiye), 06200
- Rekrutierung
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara, Central Anatolia, Türkei (türkiye), 06100
- Rekrutierung
- Gazi University
-
-
Mersin
-
Mezitli, Mersin, Türkei (türkiye), 33200
- Rekrutierung
- VM Medical Park Mersin Hospital
-
-
Suleymanpasa
-
Tekirdağ, Suleymanpasa, Türkei (türkiye), 59100
- Rekrutierung
- Tekirdag Namik Kemal University Hospital
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90095
- Rekrutierung
- David Geffen School of Medicine at UCLA
-
-
Florida
-
Plantation, Florida, Vereinigte Staaten, 33322
- Rekrutierung
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Rekrutierung
- Indiana University and Comprehensive Cancer Center
-
-
Mississippi
-
Hattiesburg, Mississippi, Vereinigte Staaten, 39401
- Rekrutierung
- Hattiesburg Clinic
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth Cancer Center
-
-
New York
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Rekrutierung
- Stony Brook University Hospital
-
Westbury, New York, Vereinigte Staaten, 11590
- Zurückgezogen
- Clinical Research Alliance Inc
-
-
North Carolina
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- Rekrutierung
- East Carolina University
-
-
Wisconsin
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- Prohealth Care Inc
-
-
-
-
-
Great Yarmouth, Vereinigtes Königreich, NR31 6LA
- Rekrutierung
- James Paget University Hospitals NHS Foundation Trust
-
Romford, Vereinigtes Königreich, RM7 0AG
- Rekrutierung
- Barking, Havering and Redbridge University Hospitals NHS Trust
-
Warwick, Vereinigtes Königreich, CV34 5BW
- Rekrutierung
- South Warwickshire NHS Foundation Trust
-
-
Cornwall
-
Truro, Cornwall, Vereinigtes Königreich, TR1 3LJ
- Rekrutierung
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
Devon
-
Plymouth, Devon, Vereinigtes Königreich, PL6 8DH
- Rekrutierung
- Derriford Hospital and the Royal Eye Infirmary
-
-
Dorset
-
Bournemouth, Dorset, Vereinigtes Königreich, BH7 7DW
- Rekrutierung
- University Hospitals Dorset
-
-
Hampshire
-
Salisbury, Hampshire, Vereinigtes Königreich, SP6 2ND
- Rekrutierung
- Salisbury Foundation Trust
-
-
Middlesex
-
Uxbridge, Middlesex, Vereinigtes Königreich, UB8 3NN
- Rekrutierung
- The Hillingdon Hospital
-
-
Surrey
-
Sutton, Surrey, Vereinigtes Königreich, SM2 5PT
- Rekrutierung
- The Royal Marsden NHS Foundation Trust
-
-
-
-
-
Vienna, Österreich, 1090
- Rekrutierung
- Medical University Vienna
-
Wels, Österreich, 4600
- Rekrutierung
- Klinikum Wels-Grieskirchen
-
-
Osterreich
-
Linz, Osterreich, Österreich, 4020
- Rekrutierung
- Ordensklinikum Linz
-
-
Upper Austria
-
Linz, Upper Austria, Österreich, 4020
- Rekrutierung
- Kepler University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
-
Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.
-
Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody, and participant should meet indication for treatment, as described in the protocol.
-
Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography [CT], or Magnetic Resonance Imaging [MRI] imaging, as described in the protocol.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Adequate hematologic and organ function, as described in the protocol.
-
All study participants must:
- Have an understanding that lenalidomide could have a potential teratogenic risk.
- Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.
- Agree not to share study medication with another person.
- Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide.
Key Exclusion Criteria:
- Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol.
- Participants with current or past histological evidence of high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.
- History of or current relevant CNS pathology, as described in the protocol.
- A malignancy other than NHL (inclusion diagnosis) unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated.
- Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
- Allergy/hypersensitivity to study drugs or excipients. as described in the protocol.
- Active infection as defined in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Odronextamab+Lenalidomide
In part 1 (safety run-in), participants with R/R indolent lymphoma (FL and MZL), will receive odronextamab in combination with lenalidomide. In part 2, 1:1 randomized participants with R/R FL and MZL, will receive odronextamab in combination with lenalidomide. |
Administered per the protocol
Andere Namen:
Administered per the protocol
Andere Namen:
|
|
Experimental: Rituximab+Lenalidomide
In part 2 only, 1:1 randomized participants with R/R FL and ML, will receive rituximab in combination with lenalidomide (R2) followed by lenalidomide monotherapy. |
Administered per the protocol
Andere Namen:
Administered per the protocol
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide
Zeitfenster: Up to 35 days
|
Part 1 |
Up to 35 days
|
|
Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide
Zeitfenster: Up to 2 years
|
Part 1 |
Up to 2 years
|
|
Severity of TEAEs for odronextamab in combination with lenalidomide
Zeitfenster: Up to 2 years
|
Part 1 |
Up to 2 years
|
|
Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR)
Zeitfenster: Up to 5 years
|
Part 2 |
Up to 5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time To Next anti-lymphoma Treatment (TTNT)
Zeitfenster: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Odronextamab concentrations in serum
Zeitfenster: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of Anti-Drug Antibodies (ADA) to odronextamab
Zeitfenster: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Magnitude of ADAs to odronextamab
Zeitfenster: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best Overall Response (BOR) as assessed by investigator review
Zeitfenster: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Duration of Response (DOR) as assessed by investigator review
Zeitfenster: Up to 5 years
|
Part 1 and Part 2 |
Up to 5 years
|
|
PFS as assessed by investigator review
Zeitfenster: Up to 5 years
|
Part 1 and Part 2 |
Up to 5 years
|
|
Complete Response (CR) as assessed by ICR
Zeitfenster: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
BOR as assessed by ICR
Zeitfenster: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Event Free Survival (EFS) as assessed by ICR
Zeitfenster: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator review
Zeitfenster: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by ICR
Zeitfenster: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Incidence of TEAEs for odronextamab in combination with lenalidomide versus R2
Zeitfenster: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs for odronextamab in combination with lenalidomide versus R2
Zeitfenster: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Overall change in Patient Reported Outcomes (PROs) as measured by scores of European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQC30)
Zeitfenster: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a Global Health Status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and GHS/QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Overall change in PROs as measured by scores of Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS)
Zeitfenster: Up to 5 years
|
Part 2 The FACT-Lym Lymphoma Subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Overall change in PROs as measured by scores of EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L)
Zeitfenster: Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ Visual Analogue Scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change from first assessment in Patient Global Impression on Severity (PGIS)
Zeitfenster: Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change from first assessment in Patient Global Impression on Change (PGIC)
Zeitfenster: Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
Change from first assessment in the Global Population item 5 (GP5) items of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire
Zeitfenster: Up to 5 years
|
Part 2 A single item (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Clinical Trial Management, Regeneron Pharmaceuticals
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Krankheitsattribute
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom, B-Zell
- Lymphom
- Pathologische Zustände, Anzeichen und Symptome
- Hämische und lymphatische Krankheiten
- Wiederauftreten
- Lymphom, follikulär
- Lymphom, B-Zelle, Randzone
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Carboxylsäuren
- Piperidine
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Antikörper, monoklonale, murine abgeleitete
- Phthalimides
- Phthalsäuren
- Säuren, carbocyclisch
- Piperidones
- Isoindolen
- Lenalidomid
- Rituximab
Andere Studien-ID-Nummern
- R1979-ONC-22102
- 2022-503092-28-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-Sharing-Zeitrahmen
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-Sharing-Zugriffskriterien
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .